Minerva Neurosciences (NERV)
NASDAQ:NERV
Top Page
Minerva Neurosciences
(NASDAQ:NERV)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.00
▲(8.89% Upside)
Action:ReiteratedDate:04/03/26
The score is held down primarily by very weak financial performance (no revenue, ongoing losses, heavy cash burn, and negative equity). Technicals also point to near-term weakness (negative MACD and price below key short-term averages). Positive corporate updates around Phase 3 planning and leadership strengthening provide some support, but do not offset the financial risk profile.
Positive Factors
Clear Phase 3 plan for roluperidone
A defined confirmatory Phase 3 with enrollment size, endpoints, and a clear timeline materially reduces clinical and execution uncertainty. Over the next 2–18 months these milestones can unlock partner interest, de-risk the program, and form the basis for financing or regulatory interactions if data are positive.
Negative Factors
No recurring revenue
With no product revenue for multiple years, the company lacks an operating cash inflow to fund development or absorb setbacks. Long-term viability depends on successful clinical outcomes, milestone payments, or dilutive financings, increasing dependency on external capital and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Clear Phase 3 plan for roluperidone
A defined confirmatory Phase 3 with enrollment size, endpoints, and a clear timeline materially reduces clinical and execution uncertainty. Over the next 2–18 months these milestones can unlock partner interest, de-risk the program, and form the basis for financing or regulatory interactions if data are positive.
Read all positive factors
Minerva Neurosciences (NERV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$238.44M
Dividend YieldN/A
Average Volume (3M)465.60K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-323.61%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding43,274,400
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.79K
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$7.00Price Target Upside27.04% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.79
Revenue Forecast (FY)N/A
Minerva Neurosciences Business Overview & Revenue Model
Company Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for th...
How the Company Makes Money
Minerva Neurosciences has historically generated little to no recurring revenue from product sales because it has been primarily a development-stage company without widely commercialized products. Its funding has primarily come from financing acti...
Minerva Neurosciences Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
7
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.44K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -15.10M | 6.02M | -21.69M | -24.69M | -45.28M |
| Net Income | -293.42M | 1.44M | -30.01M | -32.11M | -49.91M |
Balance Sheet | |||||
| Total Assets | 97.97M | 37.14M | 56.90M | 55.09M | 77.12M |
| Cash, Cash Equivalents and Short-Term Investments | 82.30M | 21.36M | 40.91M | 36.09M | 60.76M |
| Total Debt | 64.96M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 238.72M | 62.84M | 85.36M | 75.11M | 69.15M |
| Stockholders Equity | -140.75M | -25.69M | -28.46M | -20.02M | 7.98M |
Cash Flow | |||||
| Free Cash Flow | -13.51B | -19.55M | -14.78M | -24.66M | -24.60M |
| Operating Cash Flow | -13.51B | -19.55M | -14.78M | -24.65M | -24.60M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -16.33K | 0.00 |
| Financing Cash Flow | 74.45B | 0.00 | 19.60M | -5.00 | 60.00M |
Minerva Neurosciences Technical Analysis
Neutral
5.51
Price Trends
6.22
Negative
5.15
Positive
3.82
Positive
Market Momentum
-0.30
Positive
41.81
Neutral
43.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NERV, the sentiment is Neutral. The current price of 5.51 is below the 20-day moving average (MA) of 6.41, below the 50-day MA of 6.22, and above the 200-day MA of 3.82, indicating a neutral trend. The MACD of -0.30 indicates Positive momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 43.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NERV.
Minerva Neurosciences Risk Analysis
Minerva Neurosciences disclosed 75 risk factors in its most recent earnings report. Minerva Neurosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Minerva Neurosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $11.19M | -9.61 | -22.03% | ― | -41.76% | 87.36% | |
44 Neutral | $238.44M | -0.12 | 506.72% | ― | ― | -323.61% | |
43 Neutral | $4.38M | -1.58 | -79.47% | ― | -99.97% | 35.59% | |
43 Neutral | $12.01M | -1.16 | -89.92% | ― | ― | 53.19% |
* Healthcare Sector Average
NERV
Minerva Neurosciences
5.51
3.94
251.63%
BLRX
Bioline RX Ltd Sponsored ADR
2.29
-0.60
-20.76%
PULM
Pulmatrix
1.20
-4.19
-77.74%
CMMB
Chemomab Therapeutics
1.67
-3.05
-64.62%
ASBP
Aspire Biopharma Holdings
1.06
-23.74
-95.73%
Minerva Neurosciences Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
Neutral
Apr 6, 2026
Minerva Neurosciences, Inc. announced that its 2026 annual meeting of stockholders is expected to be held on June 3, 2026, a date set more than 30 days before the one-year anniversary of its 2025 annual meeting, and has therefore adjusted its time...
Business Operations and StrategyExecutive/Board Changes
Minerva Neurosciences Appoints New Chief Business Officer, Counsel
Positive
Apr 2, 2026
On March 30, 2026, Minerva Neurosciences reached a settlement agreement with longtime executive Geoffrey Race, under which he resigned as president effective March 31, 2026, and stepped down as a director of subsidiary Mind-NRG. The package provid...
Business Operations and Strategy
Minerva Outlines Confirmatory Phase 3 Plan for Roluperidone
Positive
Feb 3, 2026
Minerva Neurosciences announced that at a virtual key opinion leader event held on February 3, 2026, it would provide additional details on its proposed confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms in schizophr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.